We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Department of Justice (DOJ) has charged a Teva Pharmaceuticals subsidiary with allegedly conspiring to rig prices for generic drugs, making it the seventh drugmaker to be indicted as part of an ongoing probe. Read More
Three ranking Democrats have asked a Virginia-based consulting firm to reveal details of its government contract for Operation Warp Speed’s chief adviser Moncef Slaoui, citing concerns that the contract allows the former pharma executive to skirt ethics rules and avoid disclosing potential conflicts of interest. Read More
The Trump administration’s Aug. 24 deadline has come and gone for the pharma industry to come up with a drug pricing strategy that would prevent a threatened executive order by President Trump from going into effect — but the White House and big pharma have remained silent. Read More
The FDA has turned down Tricida’s new drug application for veverimer (TRC101) as a treatment for metabolic acidosis in patients with chronic kidney disease and said it needs to see more supporting data. Read More
AstraZeneca has denied claims that it is in talks with the U.S. government about receiving a potential Emergency Use Authorization (EUA) for its COVID-19 vaccine candidate. Read More
In a surprise U-turn, the FDA on Sunday authorized the emergency use of convalescent plasma for treating COVID-19, following accusations by President Trump that the agency was holding off on issuing an Emergency Use Authorization (EUA) for political reasons. Read More
As of Friday evening, the pharma industry had still not put forward a price-cutting strategy that could sway the president into discarding a drug pricing executive order he has threatened to enforce. Read More
President Trump is lashing out at the FDA’s decision to hold off issuing an Emergency Use Authorization (EUA) for using convalescent plasma to treat COVID-19 patients. Read More